News
NEWS - Contingency Agreement Conjectures Cellular Competition
Therapy Cell (TCEL) Australian Institute of Health and Natural Science (AIHNS)
By Carolynne Jennings, INVESTOR'S BUSINESS DAILY
Posted 04/18/2014 09:32 PM ET
The Australian Institute of Health and Natural Science (AIHNS) and Therapy Cells, Inc. (TCEL) acknowledgment the agreements for research contingency funds had been amended late Thursday, April 17th 2014. Reports that outline indenture amendments created a conduit of funding for both parties through stipulations annulled Australian legislation earlier this year. Once enacted, the enterprise will be created through a privatization of the Australian institution, the first of its kind in their definitive social economical state.
Subsequent to the announcement of Therapy Cell’s (TCEL) exclusive license from renown Dr. Casey's the word was out that principles outlined under US patent US 11/702,895, on the bid. However, and upon initial receipt, the AIHNS offer trumped the competition of the competing private foundations, a swift approach by AIHNS that may prove profitable.
Even though it priced at the low-end of an expected range, Therapy Cells Inc., (TCEL) which is being called the next (Genentech) . and Dr. Casey's patent for transformational cell therapy, is a revolutionary science which dispenses with the traditional notion that cells cannot divide once they are fully mature. Dr. Casey has shown that adult cells, given the right environment, can in fact divide and be grown in the laboratory.
Therapy Cell Inc., (TCEL) These new cells can then be used for transportation back to damaged tissue in the body, to enact tissue and organ healing. As a report noted last month,
Quote:
"With a growing level of trial success in horses, Therapy Cells' target is to gain FDA approval, and in short order have human applications in human tendons,"
Dr Casey says.
Quote:
"An initial valuation of $30 million USD for our science and technology has been appraised. FDA approval for clinical use of this technology in humans, will likely increase this factor by at least 10 times."
(Therapy Cells Inc.)
Scientists have grown stem cells from adults using cloning techniques for the first time — bringing them closer to developing patient-specific lines of cells that can be used to treat a whole host of ailments, from heart disease to blindness. The research, described in Thursday’s online edition of the journal Cell Stem Cell, is a controversial advance likely to reopen the debate over the ethics of human cloning. Therapy Cells, Inc., has expressed their gratitude to the Institute for their motions and look forward to advancing their competition to rivals like NeoStem, Inc. (NBS) ("NeoStem" or the "Company"
, a leader competitor in the emerging cellular therapy industry, who announced Monday that it has entered into a definitive agreement to acquire California Stem Cell, Inc. ("CSC", an Irvine, California based stem cell biotechnology company. As cell therapy and technology research progress alongside one another, an up rise of strong competition has built an enterprise in the market. The plantation of innovative methods conducive through strategic engineering continues prove lucrative for this sector.Therapy Cell Inc., (TCEL) mixed Q1 results. The company put in another quarter of double-digit gains, but earnings missed expectations. The downside reversal sent Chipotle back below its 50-day line.
NEWS - Contingency Agreement Conjectures Cellular Competition
Therapy Cell (TCEL) Australian Institute of Health and Natural Science (AIHNS)
By Carolynne Jennings, INVESTOR'S BUSINESS DAILY
Posted 04/18/2014 09:32 PM ET
The Australian Institute of Health and Natural Science (AIHNS) and Therapy Cells, Inc. (TCEL) acknowledgment the agreements for research contingency funds had been amended late Thursday, April 17th 2014. Reports that outline indenture amendments created a conduit of funding for both parties through stipulations annulled Australian legislation earlier this year. Once enacted, the enterprise will be created through a privatization of the Australian institution, the first of its kind in their definitive social economical state.
Subsequent to the announcement of Therapy Cell’s (TCEL) exclusive license from renown Dr. Casey's the word was out that principles outlined under US patent US 11/702,895, on the bid. However, and upon initial receipt, the AIHNS offer trumped the competition of the competing private foundations, a swift approach by AIHNS that may prove profitable.
Even though it priced at the low-end of an expected range, Therapy Cells Inc., (TCEL) which is being called the next (Genentech) . and Dr. Casey's patent for transformational cell therapy, is a revolutionary science which dispenses with the traditional notion that cells cannot divide once they are fully mature. Dr. Casey has shown that adult cells, given the right environment, can in fact divide and be grown in the laboratory.
Therapy Cell Inc., (TCEL) These new cells can then be used for transportation back to damaged tissue in the body, to enact tissue and organ healing. As a report noted last month,
Quote:
"With a growing level of trial success in horses, Therapy Cells' target is to gain FDA approval, and in short order have human applications in human tendons,"
Dr Casey says.
Quote:
"An initial valuation of $30 million USD for our science and technology has been appraised. FDA approval for clinical use of this technology in humans, will likely increase this factor by at least 10 times."
(Therapy Cells Inc.)
Scientists have grown stem cells from adults using cloning techniques for the first time — bringing them closer to developing patient-specific lines of cells that can be used to treat a whole host of ailments, from heart disease to blindness. The research, described in Thursday’s online edition of the journal Cell Stem Cell, is a controversial advance likely to reopen the debate over the ethics of human cloning. Therapy Cells, Inc., has expressed their gratitude to the Institute for their motions and look forward to advancing their competition to rivals like NeoStem, Inc. (NBS) ("NeoStem" or the "Company"
, a leader competitor in the emerging cellular therapy industry, who announced Monday that it has entered into a definitive agreement to acquire California Stem Cell, Inc. ("CSC", an Irvine, California based stem cell biotechnology company. As cell therapy and technology research progress alongside one another, an up rise of strong competition has built an enterprise in the market. The plantation of innovative methods conducive through strategic engineering continues prove lucrative for this sector.Therapy Cell Inc., (TCEL) mixed Q1 results. The company put in another quarter of double-digit gains, but earnings missed expectations. The downside reversal sent Chipotle back below its 50-day line. 
